Rigorous Characterization of Allosteric Modulation of the Human Metabotropic Glutamate Receptor 1 Reveals Probe- and Assay-Dependent Pharmacology
Allosteric modulation of metabotropic glutamate receptor subtype 1 (mGlu1) represents a viable therapeutic target for treating numerous central nervous system disorders. Although multiple chemically distinct mGlu1 positive (PAMs) and negative (NAMs) allosteric modulators have been identified, drug d...
Gespeichert in:
Veröffentlicht in: | Molecular pharmacology 2023-06, Vol.103 (6), p.325-338 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 338 |
---|---|
container_issue | 6 |
container_start_page | 325 |
container_title | Molecular pharmacology |
container_volume | 103 |
creator | Muraleetharan, Ashwin Wang, Yuyang Rowe, Matthew C. Gould, Ashleigh Gregory, Karen J. Hellyer, Shane D. |
description | Allosteric modulation of metabotropic glutamate receptor subtype 1 (mGlu1) represents a viable therapeutic target for treating numerous central nervous system disorders. Although multiple chemically distinct mGlu1 positive (PAMs) and negative (NAMs) allosteric modulators have been identified, drug discovery paradigms have not included rigorous pharmacological analysis. In the present study, we hypothesized that existing mGlu1 allosteric modulators possess unappreciated probe-dependent or biased pharmacology. Using human embryonic kidney 293 (HEK293A) cells stably expressing human mGlu1, we screened mGlu1 PAMs and NAMs from divergent chemical scaffolds for modulation of different mGlu1 orthosteric agonists in intracellular calcium (iCa2+) mobilization and inositol monophosphate (IP1) accumulation assays. Operational models of agonism and allosterism were used to derive estimates for important pharmacological parameters such as affinity, efficacy, and cooperativity. Modulation of glutamate and quisqualate-mediated iCa2+ mobilization revealed probe dependence at the level of affinity and cooperativity for both mGlu1 PAMs and NAMs. We also identified the previously described mGlu5 selective NAM PF-06462894 as an mGlu1 NAM with a different pharmacological profile from other NAMs. Differential profiles were also observed when comparing ligand pharmacology between iCa2+ mobilization and IP1 accumulation. The PAMs Ro67-4853 and CPPHA displayed apparent negative cooperativity for modulation of quisqualate affinity, and the NAMs CPCCOEt and PF-06462894 had a marked reduction in cooperativity with quisqualate in IP1 accumulation and upon extended incubation in iCa2+ mobilization assays. These data highlight the importance of rigorous assessment of mGlu1 modulator pharmacology to inform future drug discovery programs for mGlu1 allosteric modulators.
Metabotropic glutamate receptor subtype 1 (mGlu1) positive and negative allosteric modulators have therapeutic potential in multiple central nervous system disorders. We show that chemically distinct modulators display differential pharmacology with different orthosteric ligands and across divergent signaling pathways at human mGlu1. Such complexities in allosteric ligand pharmacology should be considered in future mGlu1 allosteric drug discovery programs. |
doi_str_mv | 10.1124/molpharm.122.000664 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2811939806</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0026895X24012860</els_id><sourcerecordid>2811939806</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2694-14202bca240e3111889f0456342e69002b4a4c5e47ddc9d0dee1a5ef8b26eacc3</originalsourceid><addsrcrecordid>eNp9kcFO3DAQhi3UCraUJ0BCPvaSre04Jj5wWC0tVAKBEJW4WY49ASMnDraDtH2LvnG9WuDY04xmvpnRPz9Cx5QsKWX8-xD89KTjsKSMLQkhQvA9tKANoxWhlH5CC0KYqFrZPBygLyk9E0J505J9dFALyahkbIH-3rnHEMOc8Lrs0iZDdH90dmHEoccr70Palgy-Dnb2H438BPhyHvSIryHrLuQYpgJd-DnrQWfAd2BgyiFiWtJX0D7h2xg6qLAeLV6lpDfVOUwwWhgzvt3q0Cb48Lj5ij73BYejt3iIfv_8cb--rK5uLn6tV1eVYULyinJGWGc04wTqIrdtZU94I2rOQMiivOOamwb4qbVGWmIBqG6gbzsmQBtTH6Jvu71TDC8zpKwGlwx4r0co_1CspVTWsiWioPUONTGkFKFXU3SDjhtFidp6od69UMULtfOiTJ28HZi7AezHzPvzC3C2A6DIfHUQVTIORgPWRTBZ2eD-e-AfDj6eww</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2811939806</pqid></control><display><type>article</type><title>Rigorous Characterization of Allosteric Modulation of the Human Metabotropic Glutamate Receptor 1 Reveals Probe- and Assay-Dependent Pharmacology</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><source>EZB Electronic Journals Library</source><creator>Muraleetharan, Ashwin ; Wang, Yuyang ; Rowe, Matthew C. ; Gould, Ashleigh ; Gregory, Karen J. ; Hellyer, Shane D.</creator><creatorcontrib>Muraleetharan, Ashwin ; Wang, Yuyang ; Rowe, Matthew C. ; Gould, Ashleigh ; Gregory, Karen J. ; Hellyer, Shane D.</creatorcontrib><description>Allosteric modulation of metabotropic glutamate receptor subtype 1 (mGlu1) represents a viable therapeutic target for treating numerous central nervous system disorders. Although multiple chemically distinct mGlu1 positive (PAMs) and negative (NAMs) allosteric modulators have been identified, drug discovery paradigms have not included rigorous pharmacological analysis. In the present study, we hypothesized that existing mGlu1 allosteric modulators possess unappreciated probe-dependent or biased pharmacology. Using human embryonic kidney 293 (HEK293A) cells stably expressing human mGlu1, we screened mGlu1 PAMs and NAMs from divergent chemical scaffolds for modulation of different mGlu1 orthosteric agonists in intracellular calcium (iCa2+) mobilization and inositol monophosphate (IP1) accumulation assays. Operational models of agonism and allosterism were used to derive estimates for important pharmacological parameters such as affinity, efficacy, and cooperativity. Modulation of glutamate and quisqualate-mediated iCa2+ mobilization revealed probe dependence at the level of affinity and cooperativity for both mGlu1 PAMs and NAMs. We also identified the previously described mGlu5 selective NAM PF-06462894 as an mGlu1 NAM with a different pharmacological profile from other NAMs. Differential profiles were also observed when comparing ligand pharmacology between iCa2+ mobilization and IP1 accumulation. The PAMs Ro67-4853 and CPPHA displayed apparent negative cooperativity for modulation of quisqualate affinity, and the NAMs CPCCOEt and PF-06462894 had a marked reduction in cooperativity with quisqualate in IP1 accumulation and upon extended incubation in iCa2+ mobilization assays. These data highlight the importance of rigorous assessment of mGlu1 modulator pharmacology to inform future drug discovery programs for mGlu1 allosteric modulators.
Metabotropic glutamate receptor subtype 1 (mGlu1) positive and negative allosteric modulators have therapeutic potential in multiple central nervous system disorders. We show that chemically distinct modulators display differential pharmacology with different orthosteric ligands and across divergent signaling pathways at human mGlu1. Such complexities in allosteric ligand pharmacology should be considered in future mGlu1 allosteric drug discovery programs.</description><identifier>ISSN: 0026-895X</identifier><identifier>EISSN: 1521-0111</identifier><identifier>DOI: 10.1124/molpharm.122.000664</identifier><identifier>PMID: 36921922</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Allosteric Regulation ; Glutamic Acid - metabolism ; Humans ; Ligands ; Quisqualic Acid ; Receptor, Metabotropic Glutamate 5 - metabolism</subject><ispartof>Molecular pharmacology, 2023-06, Vol.103 (6), p.325-338</ispartof><rights>2023 American Society for Pharmacology and Experimental Therapeutics</rights><rights>Copyright © 2023 by The American Society for Pharmacology and Experimental Therapeutics.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2694-14202bca240e3111889f0456342e69002b4a4c5e47ddc9d0dee1a5ef8b26eacc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36921922$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Muraleetharan, Ashwin</creatorcontrib><creatorcontrib>Wang, Yuyang</creatorcontrib><creatorcontrib>Rowe, Matthew C.</creatorcontrib><creatorcontrib>Gould, Ashleigh</creatorcontrib><creatorcontrib>Gregory, Karen J.</creatorcontrib><creatorcontrib>Hellyer, Shane D.</creatorcontrib><title>Rigorous Characterization of Allosteric Modulation of the Human Metabotropic Glutamate Receptor 1 Reveals Probe- and Assay-Dependent Pharmacology</title><title>Molecular pharmacology</title><addtitle>Mol Pharmacol</addtitle><description>Allosteric modulation of metabotropic glutamate receptor subtype 1 (mGlu1) represents a viable therapeutic target for treating numerous central nervous system disorders. Although multiple chemically distinct mGlu1 positive (PAMs) and negative (NAMs) allosteric modulators have been identified, drug discovery paradigms have not included rigorous pharmacological analysis. In the present study, we hypothesized that existing mGlu1 allosteric modulators possess unappreciated probe-dependent or biased pharmacology. Using human embryonic kidney 293 (HEK293A) cells stably expressing human mGlu1, we screened mGlu1 PAMs and NAMs from divergent chemical scaffolds for modulation of different mGlu1 orthosteric agonists in intracellular calcium (iCa2+) mobilization and inositol monophosphate (IP1) accumulation assays. Operational models of agonism and allosterism were used to derive estimates for important pharmacological parameters such as affinity, efficacy, and cooperativity. Modulation of glutamate and quisqualate-mediated iCa2+ mobilization revealed probe dependence at the level of affinity and cooperativity for both mGlu1 PAMs and NAMs. We also identified the previously described mGlu5 selective NAM PF-06462894 as an mGlu1 NAM with a different pharmacological profile from other NAMs. Differential profiles were also observed when comparing ligand pharmacology between iCa2+ mobilization and IP1 accumulation. The PAMs Ro67-4853 and CPPHA displayed apparent negative cooperativity for modulation of quisqualate affinity, and the NAMs CPCCOEt and PF-06462894 had a marked reduction in cooperativity with quisqualate in IP1 accumulation and upon extended incubation in iCa2+ mobilization assays. These data highlight the importance of rigorous assessment of mGlu1 modulator pharmacology to inform future drug discovery programs for mGlu1 allosteric modulators.
Metabotropic glutamate receptor subtype 1 (mGlu1) positive and negative allosteric modulators have therapeutic potential in multiple central nervous system disorders. We show that chemically distinct modulators display differential pharmacology with different orthosteric ligands and across divergent signaling pathways at human mGlu1. Such complexities in allosteric ligand pharmacology should be considered in future mGlu1 allosteric drug discovery programs.</description><subject>Allosteric Regulation</subject><subject>Glutamic Acid - metabolism</subject><subject>Humans</subject><subject>Ligands</subject><subject>Quisqualic Acid</subject><subject>Receptor, Metabotropic Glutamate 5 - metabolism</subject><issn>0026-895X</issn><issn>1521-0111</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcFO3DAQhi3UCraUJ0BCPvaSre04Jj5wWC0tVAKBEJW4WY49ASMnDraDtH2LvnG9WuDY04xmvpnRPz9Cx5QsKWX8-xD89KTjsKSMLQkhQvA9tKANoxWhlH5CC0KYqFrZPBygLyk9E0J505J9dFALyahkbIH-3rnHEMOc8Lrs0iZDdH90dmHEoccr70Palgy-Dnb2H438BPhyHvSIryHrLuQYpgJd-DnrQWfAd2BgyiFiWtJX0D7h2xg6qLAeLV6lpDfVOUwwWhgzvt3q0Cb48Lj5ij73BYejt3iIfv_8cb--rK5uLn6tV1eVYULyinJGWGc04wTqIrdtZU94I2rOQMiivOOamwb4qbVGWmIBqG6gbzsmQBtTH6Jvu71TDC8zpKwGlwx4r0co_1CspVTWsiWioPUONTGkFKFXU3SDjhtFidp6od69UMULtfOiTJ28HZi7AezHzPvzC3C2A6DIfHUQVTIORgPWRTBZ2eD-e-AfDj6eww</recordid><startdate>202306</startdate><enddate>202306</enddate><creator>Muraleetharan, Ashwin</creator><creator>Wang, Yuyang</creator><creator>Rowe, Matthew C.</creator><creator>Gould, Ashleigh</creator><creator>Gregory, Karen J.</creator><creator>Hellyer, Shane D.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202306</creationdate><title>Rigorous Characterization of Allosteric Modulation of the Human Metabotropic Glutamate Receptor 1 Reveals Probe- and Assay-Dependent Pharmacology</title><author>Muraleetharan, Ashwin ; Wang, Yuyang ; Rowe, Matthew C. ; Gould, Ashleigh ; Gregory, Karen J. ; Hellyer, Shane D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2694-14202bca240e3111889f0456342e69002b4a4c5e47ddc9d0dee1a5ef8b26eacc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Allosteric Regulation</topic><topic>Glutamic Acid - metabolism</topic><topic>Humans</topic><topic>Ligands</topic><topic>Quisqualic Acid</topic><topic>Receptor, Metabotropic Glutamate 5 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Muraleetharan, Ashwin</creatorcontrib><creatorcontrib>Wang, Yuyang</creatorcontrib><creatorcontrib>Rowe, Matthew C.</creatorcontrib><creatorcontrib>Gould, Ashleigh</creatorcontrib><creatorcontrib>Gregory, Karen J.</creatorcontrib><creatorcontrib>Hellyer, Shane D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Muraleetharan, Ashwin</au><au>Wang, Yuyang</au><au>Rowe, Matthew C.</au><au>Gould, Ashleigh</au><au>Gregory, Karen J.</au><au>Hellyer, Shane D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rigorous Characterization of Allosteric Modulation of the Human Metabotropic Glutamate Receptor 1 Reveals Probe- and Assay-Dependent Pharmacology</atitle><jtitle>Molecular pharmacology</jtitle><addtitle>Mol Pharmacol</addtitle><date>2023-06</date><risdate>2023</risdate><volume>103</volume><issue>6</issue><spage>325</spage><epage>338</epage><pages>325-338</pages><issn>0026-895X</issn><eissn>1521-0111</eissn><abstract>Allosteric modulation of metabotropic glutamate receptor subtype 1 (mGlu1) represents a viable therapeutic target for treating numerous central nervous system disorders. Although multiple chemically distinct mGlu1 positive (PAMs) and negative (NAMs) allosteric modulators have been identified, drug discovery paradigms have not included rigorous pharmacological analysis. In the present study, we hypothesized that existing mGlu1 allosteric modulators possess unappreciated probe-dependent or biased pharmacology. Using human embryonic kidney 293 (HEK293A) cells stably expressing human mGlu1, we screened mGlu1 PAMs and NAMs from divergent chemical scaffolds for modulation of different mGlu1 orthosteric agonists in intracellular calcium (iCa2+) mobilization and inositol monophosphate (IP1) accumulation assays. Operational models of agonism and allosterism were used to derive estimates for important pharmacological parameters such as affinity, efficacy, and cooperativity. Modulation of glutamate and quisqualate-mediated iCa2+ mobilization revealed probe dependence at the level of affinity and cooperativity for both mGlu1 PAMs and NAMs. We also identified the previously described mGlu5 selective NAM PF-06462894 as an mGlu1 NAM with a different pharmacological profile from other NAMs. Differential profiles were also observed when comparing ligand pharmacology between iCa2+ mobilization and IP1 accumulation. The PAMs Ro67-4853 and CPPHA displayed apparent negative cooperativity for modulation of quisqualate affinity, and the NAMs CPCCOEt and PF-06462894 had a marked reduction in cooperativity with quisqualate in IP1 accumulation and upon extended incubation in iCa2+ mobilization assays. These data highlight the importance of rigorous assessment of mGlu1 modulator pharmacology to inform future drug discovery programs for mGlu1 allosteric modulators.
Metabotropic glutamate receptor subtype 1 (mGlu1) positive and negative allosteric modulators have therapeutic potential in multiple central nervous system disorders. We show that chemically distinct modulators display differential pharmacology with different orthosteric ligands and across divergent signaling pathways at human mGlu1. Such complexities in allosteric ligand pharmacology should be considered in future mGlu1 allosteric drug discovery programs.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>36921922</pmid><doi>10.1124/molpharm.122.000664</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0026-895X |
ispartof | Molecular pharmacology, 2023-06, Vol.103 (6), p.325-338 |
issn | 0026-895X 1521-0111 |
language | eng |
recordid | cdi_proquest_miscellaneous_2811939806 |
source | MEDLINE; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry; EZB Electronic Journals Library |
subjects | Allosteric Regulation Glutamic Acid - metabolism Humans Ligands Quisqualic Acid Receptor, Metabotropic Glutamate 5 - metabolism |
title | Rigorous Characterization of Allosteric Modulation of the Human Metabotropic Glutamate Receptor 1 Reveals Probe- and Assay-Dependent Pharmacology |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T05%3A14%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rigorous%20Characterization%20of%20Allosteric%20Modulation%20of%20the%20Human%20Metabotropic%20Glutamate%20Receptor%201%20Reveals%20Probe-%20and%20Assay-Dependent%20Pharmacology&rft.jtitle=Molecular%20pharmacology&rft.au=Muraleetharan,%20Ashwin&rft.date=2023-06&rft.volume=103&rft.issue=6&rft.spage=325&rft.epage=338&rft.pages=325-338&rft.issn=0026-895X&rft.eissn=1521-0111&rft_id=info:doi/10.1124/molpharm.122.000664&rft_dat=%3Cproquest_cross%3E2811939806%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2811939806&rft_id=info:pmid/36921922&rft_els_id=S0026895X24012860&rfr_iscdi=true |